Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
617
datasets available to search
ShareScore release 0.9.0
Dataset results
617 results for “base population”
Accuracy of Cuffless Ambulatory Blood Pressure Monitors Compared to Cuff-based Monitors in an Ambulatory Elderly Population: A Pilot Study
ClinicalTrials.gov study NCT06358378. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark
ClinicalTrials.gov study NCT02066805. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Br
GEO Series GSE81540. Homo sapiens. 3814 samples. Type: Expression profiling by high throughput sequencing.
Genome-wide assessment of population structure and genetic diversity of Eucalyptus urophylla based on a multi-species single nucleotide polymorphism chip analysis
GEO Series GSE145072. Eucalyptus urophylla. 382 samples. Type: Genome variation profiling by SNP array; SNP genotyping by SNP array.
Peripheral T-cell lymphomas not otherwise specified correspond to distinct mature T-cell populations based on the global gene expression profile
GEO Series GSE45712. Homo sapiens. 117 samples. Type: Expression profiling by array.
Transcriptome-based mapping of m6A sites in newly synthesized mRNA population in U2OS cells.
GEO Series GSE218266. Homo sapiens. 4 samples. Type: Other.
Qialitative data WP2 and WP3: Examining acceptance, readability and comprehension of Digital communication as part of three population-based cancer screening programs
<p>Data for the the ZonMw project: <em>Examining acceptance, readability and comprehension of Digital communication as part of three population-based cancer screening programs</em></p> <p>Qualitative results of the co-creation sessions (WP2) in an excel file</p> <p>Qualitative results of the three posters for the workshop (WP3) in images</p> <p><em>Note. Part 1 (quantitative datasetwas for WP1) was stored in Zenodo, link (of persistent identifier) 10.5281/zenodo.6977196</em></p> <p><em> </em></p>
Dataset related to the article "Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based study"
<p><em>The file contains raw data related to the article "Relation between anticholinergic burden and cognitive impairment: Results from the Monzino 80-plus population-based study", available from <a href="https://onlinelibrary.wiley.com/doi/10.1002/pds.5159">https://onlinelibrary.wiley.com/doi/10.1002/pds.5159</a>.</em></p> <p> </p> <p><strong>Abstract of the manuscript:</strong></p> <p><strong>Purpose: </strong>We examined data collected in the Monzino 80-plus study to assess the relations between cognitive performance and ACB scores according to the hypothesis that a higher anticholinergic burden is associated with reduced cognitive performance.</p> <p><strong>Methods: </strong>The Monzino 80-plus is an ongoing, prospective, door-to-door population-based study started in 2002 among all residents 80 years or older in eight municipalities of Varese province, Italy. To establish the relation between cognitive impairment and the anticholinergic drug burden we recorded the ACB score for each patient at baseline. The relations between ACB score and dementia or MMSE scores were also examined after exclusion of patients taking any antipsychotic.</p> <p><strong>Results: </strong>A sample of 2140 elderly people was eligible for analysis. A significant dose-effect relationship was observed between total ACB score and diagnosis of dementia in univariate and multivariate models. Patients in ACB class ≥4 had about 4.5 times the risk of diagnosis of dementia. A relation was also found between higher ACB scores and lower MMSE scores; patients who scored 4 or more had a mean of 6.4 points lower than those not taking anticholinergic drugs. The dose-effect relationship between ACB score and diagnosis of dementia was not maintained after exclusion of patients using antipsychotics, while the association between higher ACB scores and lower MMSE scores was still present, with patients in ACB class ≥4 having a mean score about 4.4 lower.</p> <p><strong>Conclusions: </strong>There are clear relations between anticholinergic load and reduced cognitive performance, while the association with dementia remains uncertain. For primary care and geriatric clinicians, an ACB score ≥ 4 can be considered the cut-off to identify high-risk populations who may benefit from the evaluation of anticholinergic burden with the ACB scale.</p>
Daset related to article:"Trends in survival of ALS from a population-based registry"
<p>Database including all raw data related to the publication entitled "Trends in survival of ALS from a population-based registry"</p>
Dataset related to article: The role of diet on the risk of dementia in the oldest old: The Monzino 80-plus population-based study
<p>Pseudonimized single subject data relative to the results reported in the article, in .xlsx format</p>
Dataset BVOK: Examining acceptance, readability and comprehension of Digital communication as part of three population-based cancer screening programs
<p>Completed questionnaires for the ZonMw project <em>"Examining acceptance, readability and comprehension of Digital communication as part of three population-based cancer screening programs"</em>.</p>
Direct Costs of Care for Adults with Soft Tissue Sarcomas: A Population-Based Study
<p>The clinical treatment of soft tissue sarcoma (STS) has evolved substantially over the last decade. This population-based cohort study based on real-world data included all incidental STS recorded by the Veneto Cancer Registry in 2017. Data on hospital admissions, emergency department and outpatient visits, drug prescriptions, and use of medical devices within two years from STS diagnosis were obtained from administrative databases. The average per-patient real-world costs over this two-year period, in total and by single expenditure item, were calculated and stratified by stage of disease at diagnosis, tumor histology and tumor site. The mean total cost per patient amounted to EUR 16,793. A higher TNM stage at diagnosis was associated with higher healthcare costs, as follows: compared with stage I, the average total cost per patient was 1.32, 2.18 and 3.36 times greater for stages II, III and IV, respectively. Hospital stays generated the greatest costs (averaging EUR 7950 per patient), followed by outpatient visits (mean EUR 3947 per patient) and drug prescriptions (mean EUR 3664 per patient). Given the paucity of population-based studies, the present results can serve as a reference for further cost-effectiveness analyses on care strategies for patients with STS.</p>
Impact of Wide Local Excision on Melanoma Patient Survival: A Population-Based Study
<p>Promoting standardization and quality assurance (QA) in oncology on the strength of real-world data is essential to ensure better patient outcomes. Wide excision after primary tumor biopsy is a fundamental step in the therapeutic pathway for cutaneous malignant melanoma (CMM). The aim of this population-based cohort study is to assess adherence to wide local excision in a cohort of patients diagnosed with CMM and the impact of this recommended procedure on overall and disease-specific survival.This retrospective cohort study concerns CMM patients diagnosed in the Veneto region (north-east Italy) in 2017, included in the high-resolution Veneto Cancer Registry, and followed up through linkage with the regional mortality registry up until February 29th, 2020. Using population-level real-world data, linking patient-level cancer registry data with administrative records of clinical procedures may shed light on the real-world treatment of CMM patients in accordance with current guidelines. After excluding TNM stage IV patients, a Cox regression analysis was performed to test whether the completion of a wide local excision was associated with a difference in melanoma-specific and overall survival, after adjusting for other covariates. No wide excision after the initial biopsy was performed in 9.7% of cases in our cohort of 1,305 patients. After adjusting for other clinical prognostic characteristics, Cox regression revealed that failure to perform a wide local excision raised the hazard ratio of death in terms of overall survival (HR = 4.80, 95% CI: 2.05-11.22, <em>p</em> < 0.001) and melanoma-specific survival (HR = 2.84, 95% CI: 1.04-7.76, <em>p</em> = 0.042). By combining clinical and administrative data, this study on real-world clinical practice showed that almost one in ten CMM patients did not undergo wide local excision surgery. Monitoring how diagnostic-therapeutic protocols are actually implemented in the real world may contribute significantly to promoting quality improvements in the management of oncological patients.</p>
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective
<p>The prognosis of cutaneous malignant melanoma (CMM) is based on disease progression. The highly heterogeneous clinical-pathological characteristics of CMM necessitate standardized diagnostic and therapeutic interventions tailored to cancer's stage. This study utilizes clinical performance indicators to assess the quality of CMM care in Veneto (Northeast Italy). This population-based study focuses on all incidences of CMMs registered by the Veneto Cancer Registry in 2015 (1279 patients) and 2017 (1368 patients). An interdisciplinary panel of experts formulated a set of quality-monitoring indicators for diagnostic, therapeutic, and end-of-life clinical interventions for CMM. The quality of clinical care for patients was assessed by comparing the reference thresholds established by experts to the actual values obtained in clinical practice. The prevalence of stage I-CMM decreased significantly from 2015 to 2017 (from 71.8 to 62.4%; P < 0.001), and almost all the pathology reports mentioned the number of nodes dissected during a lymphadenectomy. More than 90% of advanced CMMs were promptly tested for molecular BRAF status, but the proportion of patients given targeted therapies fell short of the desired threshold (61.1%). The proportion of stage I-IIA CMM patients who inappropriately underwent computerized tomography/MRI/PET dropped from 17.4 to 3.3% ( P < 0.001). Less than 2% of patients received medical or surgical anticancer therapies in the month preceding their death. In the investigated regional context, CMM care exhibited both strengths and weaknesses. The evaluated clinical indicators shed essential insight on the clinical procedures requiring corrective action. It is crucial to monitor clinical care indicators to improve care for cancer patients and promote the sustainability of the healthcare system.</p>
Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, Republic of Kazakhstan
<p>Results of population-based age stratified seroepidemiological investigation in Kazakhstan</p>
Population-based aged-stratified seroepidemiological investigation of viral infection COVID-19 in the Republic of Kazakhstan
<p>Results of population-based age stratified seroepidemiological investigation in Kazakhstan</p>
Base data for "Interpretable semi-supervised population prediction and disaggregation using ancillary data" (full)
<p>Dataset used for experiments for the paper "Interpretable semi-supervised population prediction and disaggregation using ancillary data".</p> <p>The data comes from various sources, some of them cannot be legally redistributed; in any case, the provider of the data is clearly indicated in each folder.</p> <p> </p> <p>This version, closed from public access, contains all the data, even the non-redistributable one.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.